Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:René_Russo
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
tumor-selective immunotherapies
|
| gptkbp:focusesOn |
immuno-oncology
|
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:John_C._Williams
gptkb:Robert_Ross gptkb:David_H._Kirn gptkb:René_Russo |
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xilio Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:XLO
|
| gptkbp:website |
https://www.xiliotx.com/
|
| gptkbp:bfsParent |
gptkb:Alexandria_Venture_Investments
gptkb:Osage_University_Partners |
| gptkbp:bfsLayer |
6
|